ANI Pharmaceuticals PE Ratio 2006-2021 | ANIP

Current and historical p/e ratio for ANI Pharmaceuticals (ANIP) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ANI Pharmaceuticals PE ratio as of October 22, 2021 is 12.84.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ANI Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 36.86 0.00
2021-06-30 35.05 $-1.42 0.00
2021-03-31 36.14 $-1.28 0.00
2020-12-31 29.04 $-1.88 0.00
2020-09-30 28.21 $-1.99 0.00
2020-06-30 32.34 $-1.71 0.00
2020-03-31 40.74 $-0.15 0.00
2019-12-31 61.67 $0.48 128.48
2019-09-30 72.88 $1.35 53.99
2019-06-30 82.20 $1.45 56.69
2019-03-31 70.54 $1.15 61.34
2018-12-31 45.02 $1.30 34.63
2018-09-30 56.54 $0.01 5654.00
2018-06-30 66.80 $-0.01 0.00
2018-03-31 58.22 $-0.01 0.00
2017-12-31 64.45 $-0.10 0.00
2017-09-30 52.49 $0.64 82.02
2017-06-30 46.80 $0.46 101.74
2017-03-31 49.51 $0.33 150.03
2016-12-31 60.62 $0.35 173.20
2016-09-30 66.35 $0.69 96.16
2016-06-30 55.82 $0.86 64.91
2016-03-31 33.66 $1.07 31.46
2015-12-31 45.13 $1.33 33.93
2015-09-30 39.51 $2.90 13.62
2015-06-30 62.05 $3.10 20.02
2015-03-31 62.55 $2.58 24.24
2014-12-31 56.39 $2.53 22.29
2014-09-30 28.28 $1.07 26.43
2014-06-30 34.44 $0.61 56.46
2014-03-31 31.35 $-5.20 0.00
2013-12-31 20.08 $-6.07 0.00
2013-09-30 9.77 $-7.39 0.00
2013-06-30 6.00 $-9.14 0.00
2013-03-31 7.02 $-5.28 0.00
2012-12-31 7.38 $-7.98 0.00
2012-09-30 11.34 $-9.18 0.00
2012-06-30 15.30 $-11.88 0.00
2012-03-31 24.48 $-15.47 0.00
2011-12-31 18.08 $-19.43 0.00
2011-09-30 82.08 $-23.75 0.00
2011-06-30 99.00 $-25.19 0.00
2011-03-31 71.28 $-25.55 0.00
2010-12-31 59.04 $-25.19 0.00
2010-09-30 60.48 $-48.94 0.00
2010-06-30 63.36 $-50.74 0.00
2010-03-31 64.44 $-50.74 0.00
2009-12-31 52.20 $-49.30 0.00
2009-09-30 71.28 $-20.87 0.00
2009-06-30 72.00 $-21.95 0.00
2009-03-31 47.52 $-23.75 0.00
2008-12-31 36.00 $-23.03 0.00
2008-09-30 176.04 $-23.39 0.00
2008-06-30 170.64 $-16.91 0.00
2008-03-31 164.16 $-12.59 0.00
2007-12-31 136.08 $-10.80 0.00
2007-09-30 208.80 $7.20 29.01
2007-06-30 228.24 $8.28 27.58
2007-03-31 214.92 $7.92 27.15
2006-12-31 99.72 $4.68 21.31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.470B $0.208B
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76